AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. OGEN
  4. [Form 4] Oragenics Inc. Insider Trading Activity

[Form 4] Oragenics Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Key takeaways from Oragenics Inc. (OGEN) Form 4:

  • Reporting person: Odyssey Health, Inc., designated as a 10% owner.
  • Two open-market sales of common stock were disclosed.
  • 17 Jun 2025: 2,000 shares sold at $4.46.
  • 18 Jun 2025: 5,044 shares sold at $4.26.

After completing these transactions, Odyssey Health reports 0 shares of Oragenics common stock remaining, indicating a full divestiture of its previously reportable stake. All transactions were coded 鈥淪鈥� (sale) and were executed directly; no derivative securities or additional transactions were reported.

Punti chiave dal modulo Form 4 di Oragenics Inc. (OGEN):

  • Persona segnalante: Odyssey Health, Inc., indicata come detentrice del 10%.
  • Due vendite di azioni ordinarie sul mercato aperto sono state comunicate.
  • 17 giu 2025: vendute 2.000 azioni a $4,46.
  • 18 giu 2025: vendute 5.044 azioni a $4,26.

Dopo queste operazioni, Odyssey Health dichiara di non possedere pi霉 azioni ordinarie di Oragenics, segnalando una completa dismissione della quota precedentemente detenuta. Tutte le transazioni sono state classificate come 鈥淪鈥� (vendita) ed eseguite direttamente; non sono stati riportati titoli derivati o altre transazioni.

Puntos clave del Formulario 4 de Oragenics Inc. (OGEN):

  • Persona informante: Odyssey Health, Inc., designada como propietaria del 10%.
  • Se divulgaron dos ventas en el mercado abierto de acciones comunes.
  • 17 jun 2025: 2,000 acciones vendidas a $4.46.
  • 18 jun 2025: 5,044 acciones vendidas a $4.26.

Tras completar estas transacciones, Odyssey Health reporta 0 acciones comunes de Oragenics, indicando una desinversi贸n total de su participaci贸n previamente reportada. Todas las transacciones fueron codificadas como 鈥淪鈥� (venta) y se ejecutaron directamente; no se reportaron valores derivados ni transacciones adicionales.

Oragenics Inc.(OGEN) Form 4 欤检殧 雮挫毄:

  • 氤搓碃鞛�: Odyssey Health, Inc., 10% 靻岇湢鞛愲 歆�鞝曤惃.
  • 氤错喌欤� 瓿店皽鞁滌灔 毵る弰 2瓯挫澊 瓿店皽霅�.
  • 2025雲� 6鞗� 17鞚�: 2,000欤缄皜 $4.46鞐� 毵る弰霅�.
  • 2025雲� 6鞗� 18鞚�: 5,044欤缄皜 $4.26鞐� 毵る弰霅�.

鞚� 瓯半灅 鞕勲 頉� Odyssey Health電� Oragenics 氤错喌欤� 0欤�毳� 氤挫湢頃橁碃 鞛堨潓鞚� 氤搓碃頃橃棳 鞚挫爠鞐� 氤搓碃霅� 歆�攵勳潉 鞝勲秬 毵り皝頄堨潓鞚� 雮橅儉雰呺媹雼�. 氇摖 瓯半灅電� 鈥淪鈥�(毵る弰)搿� 攵勲霅橃棃鞙茧┌ 歆侅爲 鞁ろ枆霅橃棃瓿�, 韺岇儩歃濌秾鞚措倶 於旉皜 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

Points cl茅s du formulaire Form 4 d'Oragenics Inc. (OGEN) :

  • Personne d茅clarant : Odyssey Health, Inc., d茅sign茅e comme propri茅taire 脿 10 %.
  • Deux ventes d鈥檃ctions ordinaires sur le march茅 libre ont 茅t茅 divulgu茅es.
  • 17 juin 2025 : 2 000 actions vendues 脿 4,46 $.
  • 18 juin 2025 : 5 044 actions vendues 脿 4,26 $.

Apr猫s ces transactions, Odyssey Health d茅clare ne plus d茅tenir aucune action ordinaire d鈥橭ragenics, indiquant une cession totale de sa participation pr茅c茅demment d茅clar茅e. Toutes les transactions ont 茅t茅 cod茅es 芦 S 禄 (vente) et ex茅cut茅es directement ; aucun titre d茅riv茅 ni transaction suppl茅mentaire n鈥檃 茅t茅 signal茅.

Wichtige Erkenntnisse aus dem Form 4 von Oragenics Inc. (OGEN):

  • Meldende Person: Odyssey Health, Inc., als 10%-Eigent眉mer ausgewiesen.
  • Zwei Verk盲ufe von Stammaktien am offenen Markt wurden offengelegt.
  • 17. Juni 2025: 2.000 Aktien zu $4,46 verkauft.
  • 18. Juni 2025: 5.044 Aktien zu $4,26 verkauft.

Nach Abschluss dieser Transaktionen meldet Odyssey Health 0 Aktien von Oragenics Stammaktien, was auf eine vollst盲ndige Ver盲u脽erung des zuvor gemeldeten Anteils hinweist. Alle Transaktionen wurden mit 鈥濻鈥� (Verkauf) codiert und direkt ausgef眉hrt; keine Derivate oder zus盲tzliche Transaktionen wurden gemeldet.

Positive
  • None.
Negative
  • 10% owner Odyssey Health sold 7,044 shares over two days and now holds zero OGEN shares, representing a full exit.
  • No insider purchases or positive insider activity were reported in this filing.

Insights

TL;DR: 10% owner Odyssey Health liquidates entire OGEN stake鈥�7,044 shares鈥攙ia two sales at $4.46 and $4.26; negative insider signal.

Odyssey Health鈥檚 Form 4 shows back-to-back sales totaling 7,044 shares. Post-sale beneficial ownership is now zero, meaning the entity is no longer an insider under the 10% threshold. While the filing offers no motive, a complete exit by a significant holder often raises investor concern about near-term prospects or valuation. No offsetting insider purchases or derivative activity appear in the filing, reinforcing the negative read-through for sentiment-driven investors.

TL;DR: Complete divestiture ends Odyssey Health鈥檚 Section 16 reporting duty; material change in insider ownership structure.

The Form 4 indicates Odyssey Health is relinquishing its insider status by reducing holdings to zero. Such shifts can alter governance dynamics: proxy influence, voting power, and continued disclosure obligations all diminish once the 10% threshold is crossed in reverse. No 10b5-1 plan is referenced, so the sales appear discretionary. Given the magnitude relative to total holdings (100% disposition), the development is impactful for monitoring future ownership concentration and potential shifts in strategic control.

Punti chiave dal modulo Form 4 di Oragenics Inc. (OGEN):

  • Persona segnalante: Odyssey Health, Inc., indicata come detentrice del 10%.
  • Due vendite di azioni ordinarie sul mercato aperto sono state comunicate.
  • 17 giu 2025: vendute 2.000 azioni a $4,46.
  • 18 giu 2025: vendute 5.044 azioni a $4,26.

Dopo queste operazioni, Odyssey Health dichiara di non possedere pi霉 azioni ordinarie di Oragenics, segnalando una completa dismissione della quota precedentemente detenuta. Tutte le transazioni sono state classificate come 鈥淪鈥� (vendita) ed eseguite direttamente; non sono stati riportati titoli derivati o altre transazioni.

Puntos clave del Formulario 4 de Oragenics Inc. (OGEN):

  • Persona informante: Odyssey Health, Inc., designada como propietaria del 10%.
  • Se divulgaron dos ventas en el mercado abierto de acciones comunes.
  • 17 jun 2025: 2,000 acciones vendidas a $4.46.
  • 18 jun 2025: 5,044 acciones vendidas a $4.26.

Tras completar estas transacciones, Odyssey Health reporta 0 acciones comunes de Oragenics, indicando una desinversi贸n total de su participaci贸n previamente reportada. Todas las transacciones fueron codificadas como 鈥淪鈥� (venta) y se ejecutaron directamente; no se reportaron valores derivados ni transacciones adicionales.

Oragenics Inc.(OGEN) Form 4 欤检殧 雮挫毄:

  • 氤搓碃鞛�: Odyssey Health, Inc., 10% 靻岇湢鞛愲 歆�鞝曤惃.
  • 氤错喌欤� 瓿店皽鞁滌灔 毵る弰 2瓯挫澊 瓿店皽霅�.
  • 2025雲� 6鞗� 17鞚�: 2,000欤缄皜 $4.46鞐� 毵る弰霅�.
  • 2025雲� 6鞗� 18鞚�: 5,044欤缄皜 $4.26鞐� 毵る弰霅�.

鞚� 瓯半灅 鞕勲 頉� Odyssey Health電� Oragenics 氤错喌欤� 0欤�毳� 氤挫湢頃橁碃 鞛堨潓鞚� 氤搓碃頃橃棳 鞚挫爠鞐� 氤搓碃霅� 歆�攵勳潉 鞝勲秬 毵り皝頄堨潓鞚� 雮橅儉雰呺媹雼�. 氇摖 瓯半灅電� 鈥淪鈥�(毵る弰)搿� 攵勲霅橃棃鞙茧┌ 歆侅爲 鞁ろ枆霅橃棃瓿�, 韺岇儩歃濌秾鞚措倶 於旉皜 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

Points cl茅s du formulaire Form 4 d'Oragenics Inc. (OGEN) :

  • Personne d茅clarant : Odyssey Health, Inc., d茅sign茅e comme propri茅taire 脿 10 %.
  • Deux ventes d鈥檃ctions ordinaires sur le march茅 libre ont 茅t茅 divulgu茅es.
  • 17 juin 2025 : 2 000 actions vendues 脿 4,46 $.
  • 18 juin 2025 : 5 044 actions vendues 脿 4,26 $.

Apr猫s ces transactions, Odyssey Health d茅clare ne plus d茅tenir aucune action ordinaire d鈥橭ragenics, indiquant une cession totale de sa participation pr茅c茅demment d茅clar茅e. Toutes les transactions ont 茅t茅 cod茅es 芦 S 禄 (vente) et ex茅cut茅es directement ; aucun titre d茅riv茅 ni transaction suppl茅mentaire n鈥檃 茅t茅 signal茅.

Wichtige Erkenntnisse aus dem Form 4 von Oragenics Inc. (OGEN):

  • Meldende Person: Odyssey Health, Inc., als 10%-Eigent眉mer ausgewiesen.
  • Zwei Verk盲ufe von Stammaktien am offenen Markt wurden offengelegt.
  • 17. Juni 2025: 2.000 Aktien zu $4,46 verkauft.
  • 18. Juni 2025: 5.044 Aktien zu $4,26 verkauft.

Nach Abschluss dieser Transaktionen meldet Odyssey Health 0 Aktien von Oragenics Stammaktien, was auf eine vollst盲ndige Ver盲u脽erung des zuvor gemeldeten Anteils hinweist. Alle Transaktionen wurden mit 鈥濻鈥� (Verkauf) codiert und direkt ausgef眉hrt; keine Derivate oder zus盲tzliche Transaktionen wurden gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Odyssey Health, Inc.
(Last) (First) (Middle)
2300 WEST SAHARA AVENUE,
SUITE 800 - #4012
(Street)
LAS VEGAS NV 89102
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ORAGENICS INC [ OGEN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock - OGEN 06/17/2025 06/17/2025 S 2,000 D $4.46 5,044 D
Common Stock - OGEN 06/18/2025 06/18/2025 S 5,044 D $4.26 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Christine M. Farrell, CFO 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many Oragenics (OGEN) shares did Odyssey Health sell?

Odyssey Health sold 7,044 shares in total.

At what prices were the OGEN shares sold?

Shares were sold at $4.46 on 17 Jun 2025 and $4.26 on 18 Jun 2025.

What is Odyssey Health's remaining stake in Oragenics after the transactions?

Following the sales, Odyssey Health reports 0 shares, indicating a complete divestiture.

Were any derivative securities involved in the Form 4 filing?

No. The filing lists no derivative security transactions or holdings.

Does Odyssey Health remain a Section 16 insider after these sales?

With beneficial ownership now at 0 shares, Odyssey Health is no longer a 10% owner and may cease Section 16 insider status.
Stock OGEN logo
Oragenics

NYSE:OGEN

OGEN Rankings

#10727 Ranked by Market Cap
N/A Ranked by Dividends
#168 Top Gainer

OGEN Latest News

Jul 1, 2025
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
Jun 10, 2025
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
May 28, 2025
Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
May 13, 2025
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
May 12, 2025
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

OGEN Latest SEC Filings

Jul 1, 2025
[EFFECT] Oragenics Inc. SEC Filing
Jun 30, 2025
[S-1/A] Oragenics Inc. Amends IPO Registration Statement
Jun 23, 2025
[S-1] Oragenics Inc. Files IPO Registration Statement

OGEN Stock Data

2.55M
698.42k
13.3%
1.14%
2.86%
Biotechnology
Pharmaceutical Preparations
United States
SARASOTA